Cargando…
Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) remains a lethal disease with a 5-year survival of 4%. A key hallmark of PDAC is extensive stromal involvement, which makes capturing precise tumor-specific molecular information difficult. Here, we have overcome this problem by applying blind source separatio...
Autores principales: | Moffitt, Richard A., Marayati, Raoud, Flate, Elizabeth L., Volmar, Keith E., Loeza, S. Gabriela Herrera, Hoadley, Katherine A., Rashid, Naim U., Williams, Lindsay A., Eaton, Samuel C., Chung, Alexander H., Smyla, Jadwiga K., Anderson, Judy M., Kim, Hong Jin, Bentrem, David J., Talamonti, Mark S., Iacobuzio-Donahue, Christine A., Hollingsworth, Michael A., Yeh, Jen Jen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912058/ https://www.ncbi.nlm.nih.gov/pubmed/26343385 http://dx.doi.org/10.1038/ng.3398 |
Ejemplares similares
-
A Six-Gene Signature Predicts Survival of Patients with Localized Pancreatic Ductal Adenocarcinoma
por: Stratford, Jeran K., et al.
Publicado: (2010) -
Hexokinase 2 promotes tumor growth and metastasis by regulating lactate production in pancreatic cancer
por: Anderson, Marybeth, et al.
Publicado: (2016) -
Pancreatic cancer stem cells may define tumor stroma characteristics and recurrence patterns in pancreatic ductal adenocarcinoma
por: Askan, Gokce, et al.
Publicado: (2021) -
Immunotherapy in Pediatric Solid Tumors—A Systematic Review
por: Marayati, Raoud, et al.
Publicado: (2019) -
Metformin Treatment Does Not Inhibit Growth of Pancreatic Cancer Patient-Derived Xenografts
por: Lipner, Matthew B., et al.
Publicado: (2016)